Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|August 28, 2020
- Pharmaceutical Technology's In the Lab eNewsletter 09-02-2020
- Volume 15
- Issue 9
Swittons Introduces IoT-Enabled Smart Devices for Pharmaceutical Labs
Author(s)Pharmaceutical Technology Editors
With the ability to be uniquely programmed, the devices provide user interfaces that can integrate with other systems and IoT devices, giving labs the ability to create their own Lab of the Future initiatives.
Advertisement
Swittons, a P360 company, introduced a new line of Internet of Things (IoT)-enabled smart devices for pharmaceutical labs. The devices work to automate laboratory workflows between people and existing digital lab equipment, systems, and solutions.
With the ability to be uniquely programmed, the devices provide user interfaces that can integrate with other systems and IoT devices, giving labs the ability to create their own Lab of the Future initiatives. Additionally, the new devices are compatible with laboratory information management systems, eDOC, and ticketing systems and feature a backend portal and reporting system.
“There are profound changes taking place in the area of life science research and development,” said Anupam Nandwana, Swittons’ CEO and founder, in an Aug. 11, 2020 company press release. “Driven by technological advances and the development of precision medicines, these modernization initiatives are designed to propel laboratory efficiencies into the future, allowing scientists to spend more time on science. This has changed the very concept of what the lab is, and Swittons is a key part of that evolution.”
Source:
Articles in this issue
about 6 years ago
Outlining Drug Stability and Solubility with Dissolution Testingabout 6 years ago
Dotmatics Launches Bioregister 2020.1about 6 years ago
Thermo Fisher and CROs Expand Access to Cryo-EMabout 6 years ago
Lonza Expands its Microbial Manufacturing Facility in Switzerlandabout 6 years ago
PPD and Pfizer Enter into Three-Year AgreementAdvertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
3
PharmTech’s Weekly Roundup—November 6, 2026: Impurities, Supply Resilience, and AI Accountability
4
Our Biggest Takeaways From AAPS PharmSci 360
5